MedicineCardiologyEndocrinologyCardiovascular PharmacotherapyEndocrine PharmacotherapyReproductive EndocrinologyAndrogen PhysiologyAndrogen TherapyCardiovascular AgingCardiovascular DiseaseCoronary Artery DiseaseIschemic Heart DiseaseAging Male EndocrinologyAndrogen PharmacologyAndrogen ProfileCardiac Doppler EchocardiographyCardiac Systolic FunctionMyocardial Ischemia Markers
The elevated estradiol/testosterone (E2/T) ratio had been proved to be a risk factor for coronary heart disease (CHD) in elderly men. We conducted a randomized placebo controlled crossover study on the effects of a new androgenic preparation "Andriol" in 62 elderly men with CHD over a period of 2.5 months. The results showed significant differences between Andriol- and placebo-treated groups at the end of this period: in the former, serum T level was elevated significantly (P < 0.001), E2 level was unchanged (P > 0.05), E2/T ratio was reduced (P < 0.05), angina pectoris (AP) was relieved (total effective rate, 77.4%), and myocardial ischemia in ECG and Holter recordings were improved (total effective rate, respectively 68.8% and 75%). Doppler echocardiography showed that 12 parameters of cardiac function were unchanged in both groups. No obvious side effect was found in those who took Andriol.